AngioDynamics, Inc. reaffirms earning guidance for fiscal year 2024. The Company continues to expect its fiscal year 2024 net sales to be in the range of $328 to $333 million and gross margin to be approximately 50% to 52%. For comparison, pro forma revenue, gross margin, and adjusted loss per share for FY23 when excluding the assets divested to Merit Medical were $306.3 million, 50.5%, and $0.43, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.05 USD | -1.14% | -3.51% | -22.83% |
May. 06 | AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV) | CI |
Apr. 08 | North American Morning Briefing : Inflation Data, -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.83% | 242M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.70% | 40.7B | |
+24.51% | 32.3B | |
+3.43% | 26.53B | |
-0.32% | 24.96B |
- Stock Market
- Equities
- ANGO Stock
- News AngioDynamics, Inc.
- AngioDynamics, Inc. Reaffirms Earning Guidance for Fiscal Year 2024